Which regimens are used for maintenance therapy in multiple myeloma?

Updated: Aug 14, 2019
  • Author: Sara J Grethlein, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Meta-analysis suggests benefit in progression-free survival (PFS) and overall survival with lenalidomide maintenance therapy. The following regimens have been used successfully:

  • Lenalidomide 10 mg/day on days 1-21 every 28d [34]   or
  • Lenalidomide 10 mg/day

PFS benefit was also observed in a phase III study of bortezomib and ixazomib compared with placebo. These agents can be alternatives to lenalidomide, particularly in patients with lenalidomide intolerance or renal failure. [7] Bortezomib-mediated neuropathy is common with long-term use, however, so patients require close monitoring and dose titration if side effects occur.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!